Table 1.
Patients, diagnoses, pulmonary status at enrolment, and positive episodes
| Case | Diagnosis | Bronchiectasis at enrolment | Lung function at enrolment | Gender | Age: years | Positive episodes | Symptomatic during viral episodes |
|---|---|---|---|---|---|---|---|
| 1 | CTLA‐4 haploinsufficiency | No | Restrictive | Female | 11.7 | ADV (January) | Yes |
| RV (April) | Yes | ||||||
| Coronavirus + RV (September) | No | ||||||
| 2 | CVID | No | Restrictive | Female | 12.5 | RV (December) | Yes |
| RV (April) | Yes | ||||||
| RV (June) | Yes | ||||||
| 3 | No | Restrictive | Female | 16.9 | ‐ | ||
| 4 | XLA | No | Normal | Male | 18.8 | RV (December) | Yes |
| Influenza A (February) | Yes | ||||||
| RV (September) | Yes | ||||||
| 5 | No | Normal | Male | 5.7 | ‐ | ||
| 6 | Yes | Normal | Male | 17.8 | ‐ | ||
| 7 | ARA | No | Normal | Female | 7.8 | RV (November) | Yes |
| RV (June) | Yes | ||||||
| 8 | No | NA | Male | 4.8 | ADV (September) | Yes | |
| RV (October) | Yes | ||||||
| ADV (November) | Yes | ||||||
| 9 | B‐cell lymphopenia after HSCT due to CID more than 3 years ago | Yes | Normal | Male | 7.6 | ‐ | |
| 10 | No | Normal | Male | 15.3 | RSV(January) | Yes | |
| 11 | No | Normal | Male | 18 | ‐ | ||
| 12 | APDS2 | No | Normal | Male | 14.9 | ‐ | |
| 13 | AD‐HIES | Yes | Normal | Female | 12 | RV (November) | No |
| RV (September) | Yes | ||||||
| 14 | Secondary HID after rituximab for refractory nephrotic syndrome | No | NA | Male | 4.7 | RV (December) | Yes |
AD‐HIES, autosomal dominant Hyper IgE syndrome; ADV, adenovirus; APDS2, activated PI3 kinase delta syndrome; ARA, autosomal recessive agammaglobulinemia; CID, combined immunodeficiency; CVID, common variable immunodeficiency; HID, humoral immunodeficiency; HSCT, hematopoietic stem cell transplantation; NA, not available (young children); RSV, respiratory syncytial virus; RV, rhinovirus; XLA, X‐linked agammaglobulinemia.
This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.